Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the ...
Univeristy of Iowa Daily Iowan: Advancements in cystic fibrosis treatment bring about life changes in patients
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly ...
Business Wire: Porosome Therapeutics, Inc. Files Comprehensive Patent for New Generation of Treatments for Cystic Fibrosis and Other Diseases
Porosome Therapeutics, Inc. Files Comprehensive Patent for New Generation of Treatments for Cystic Fibrosis and Other Diseases
Three scientists who revolutionized the treatment of cystic fibrosis and prolonged the lifespan of patients with the deadly disease have won the Lasker Award, one of the most prestigious awards in ...
News Medical: Cystic fibrosis patients on triple-drug therapy can safely reduce daily lung treatments
Cystic fibrosis patients on triple-drug therapy can safely reduce daily lung treatments
For cystic fibrosis (CF) patients with multi-drug resistant (MDR) bacterial infections, experimental treatment with bacteriophage (or phage) has yielded good results with apparent safety so far, a ...
Medscape: Novel Once-Daily Cystic Fibrosis Treatment Matches Standard Therapy in Phase 3 Trials
Novel Once-Daily Cystic Fibrosis Treatment Matches Standard Therapy in Phase 3 Trials
Business Wire: Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis
Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis